Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Neurosci. 2008 Aug;9(8):638-46. doi: 10.1038/nrn2453. Epub 2008 Jul 16.

How can we realize the promise of personalized antidepressant medicines?

Author information

  • 1Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. holsboer@mpipsykl.mpg.de

Abstract

Personalized medication that is based on pharmacogenetic data has long been expected to improve the efficacy of treatments for neurological and psychiatric disorders, including depression. However, the complexity of the regulation of gene transcription and its interactions with environmental factors means that straightforward translation of individual genetic information into tailored treatment is unlikely. Nevertheless, when data from genomics, proteomics, metabolomics, neuroimaging and neuroendocrinology are used in combination, they could lead to the development of effective personalized antidepressant treatment that is based on both genotypes and biomarkers. This process will require many further steps and collaboration between basic and clinical neuroscience.

PMID:
18628772
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk